6-methylthiopurine has been researched along with Premature Birth in 1 studies
6-methylthiopurine : A thiopurine that is 9H-purine substituted by a methylsulfanyl group at position 6.
Premature Birth: CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies." | 1.62 | Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. ( Beukers, R; Bodelier, A; de Boer, N; de Lima, A; Depla, ACTM; Dijkstra, G; Erler, N; Escher, JC; Gilissen, L; Hoentjen, F; Jansen, JM; Kanis, SL; Kuyvenhoven, J; Mahmmod, N; Mallant-Hent, RC; Modderman, S; Noruzi, A; Oldenburg, B; Oostenbrug, LE; Pierik, M; Romberg-Camps, M; Ter Borg, PCJ; Thijs, W; van der Meulen-de Jong, AE; van der Woude, CJ; van Dijk, ARM; West, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanis, SL | 1 |
| Modderman, S | 1 |
| Escher, JC | 1 |
| Erler, N | 1 |
| Beukers, R | 1 |
| de Boer, N | 1 |
| Bodelier, A | 1 |
| Depla, ACTM | 1 |
| Dijkstra, G | 1 |
| van Dijk, ARM | 1 |
| Gilissen, L | 1 |
| Hoentjen, F | 1 |
| Jansen, JM | 1 |
| Kuyvenhoven, J | 1 |
| Mahmmod, N | 1 |
| Mallant-Hent, RC | 1 |
| van der Meulen-de Jong, AE | 1 |
| Noruzi, A | 1 |
| Oldenburg, B | 1 |
| Oostenbrug, LE | 1 |
| Ter Borg, PCJ | 1 |
| Pierik, M | 1 |
| Romberg-Camps, M | 1 |
| Thijs, W | 1 |
| West, R | 1 |
| de Lima, A | 1 |
| van der Woude, CJ | 1 |
1 other study available for 6-methylthiopurine and Premature Birth
| Article | Year |
|---|---|
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Topics: Adalimumab; Adult; Anti-Bacterial Agents; Autoimmune Diseases; Cesarean Section; Child Development; | 2021 |